
ACRS
USDAclaris Therapeutics Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.260
High
$1.360
Low
$1.260
Volume
0.07M
Company Fundamentals
Market Cap
144.9M
Industry
Diagnostics & Research
Country
United States
Trading Stats
Avg Volume
0.92M
Exchange
NMS
Currency
USD
52-Week Range
AI Analysis Report
Last updated: Apr 22, 2025[ACRS: Aclaris Therapeutics Inc.] - Is This Stock Ready to Bounce? A Quick Look
Stock Symbol: ACRS Generate Date: 2025-04-22 07:56:22
Alright, let's break down what's happening with Aclaris Therapeutics (ACRS). For folks who aren't glued to stock tickers all day, we're going to look at the recent news, how the stock price has been moving, and what some smart systems are predicting. Think of it like checking the weather forecast for your investments.
What's the News Buzz? Good Vibes Only?
Actually, yeah, pretty positive news just dropped. A big bank called Scotiabank started covering Aclaris, and they're saying it's a "Sector Outperform." In plain English, that means they think Aclaris is likely to do better than other companies in the same business. They even set a price target way up at $15. That's a big jump from where the stock is now. This kind of analyst thumbs-up can often give a stock a boost because it signals to other investors that maybe this company is worth a closer look. So, news-wise, it's a definite green light.
Price Check: Where's the Stock Been Lately?
Now, let's peek at the stock chart for the last month or so. If you look back to late January and February, ACRS was trading around $2.50 - $2.60. Then, things got a bit bumpy. From late February into March, the price mostly drifted downwards, hitting lows around $1.50 - $1.60. More recently, especially in April, it's been sliding further, even dipping below $1.20. It looks like the stock has been in a pretty clear downtrend for a while.
However, and this is interesting, the very latest price action seems to be trying to stabilize around the $1.10 - $1.20 level. It's not shooting up, but it's not collapsing either. Think of it like a car hitting the brakes after going downhill.
Now, what about those AI predictions? They're saying a tiny percentage increase for today and the next couple of days – like less than 1% each day. Honestly, those numbers are so small they're almost background noise. But, the direction is still slightly positive, according to the AI.
Putting It Together: Possible Bounce or More Downhill?
Okay, so we've got positive news from an analyst, a stock price that's been falling but might be finding a bottom, and AI predictions that are barely budging upwards. What does this all mean for you and me?
Here's the thing: that analyst upgrade is a significant positive signal. Big banks don't just throw out "Outperform" ratings for fun. It suggests they see real potential in Aclaris. The fact that the stock price has been beaten down recently could actually be an opportunity. It's like a sale on a stock that just got a good review.
Potential Lean: Right now, the situation leans slightly towards a potential buying opportunity. It's not a screaming "buy now!" signal, but it's worth paying attention to. The stock seems to be trying to find a floor after a pretty steep drop.
Thinking about Entry? If you were considering dipping your toes in, the current price range around $1.13 - $1.14 might be an area to watch. It's close to recent lows, and the recommendation data even mentions $1.13 and $1.14 as potential entry points. If the stock holds around this level and starts to show some upward momentum, it could be a sign of a turnaround.
What about getting out? For managing risk, a stop-loss around $1.02 makes sense. That's a bit below recent lows, so if it drops below that, it might be a sign the downtrend is still in charge. For taking profits, the recommendation data suggests a take-profit around $1.23. That's a modest target, but in the short term, capturing a small bounce could be a reasonable goal. Of course, the analyst price target is way higher at $15, but that's a long way off and might take time to play out, if it ever does.
Quick Company Context: Aclaris is in the business of developing drugs for skin and immune-related diseases. That analyst upgrade likely means they see something promising in Aclaris's pipeline or market position. Keep in mind they are a smaller company, which can mean more volatility – both up and down.
In short: ACRS looks interesting right now. Positive news is battling a recent downtrend. It's not a slam dunk, but for someone looking for a potentially undervalued stock with a recent positive catalyst, ACRS could be worth further research. Watch that $1.10 - $1.20 price range closely.
Disclaimer: Please remember, this is just an analysis based on the data provided and is for informational purposes only. This is not financial advice. Investing in the stock market involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.
Related News
Scotiabank Initiates Coverage On Aclaris Therapeutics with Sector Outperform Rating, Announces Price Target of $15
Scotiabank analyst Louise Chen initiates coverage on Aclaris Therapeutics with a Sector Outperform rating and announces Price Target of $15.
AI PredictionBeta
AI Recommendation
Updated at: Apr 27, 2025, 08:03 PM
66.0% Confidence
Risk & Trading
Entry Point
$1.33
Take Profit
$1.46
Stop Loss
$1.21
Key Factors
Related Stocks

BFLY
Butterfly Network Inc.

PRGS
Progress Software Corporation (DE)

EOD
Allspring Global Dividend Opportunity Fund Common Shares of Beneficial Interest

RAMP
LiveRamp Holdings Inc.

MSEX
Middlesex Water Company
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.